CAD Staging Guide

The first clinical staging system for disease burden of atherosclerotic plaque, which is the direct cause of coronary artery disease (CAD).

Access Our CAD Staging Guide
The goal of the staging system is to be able to standardize disease severity based on the primary cause of CAD—atherosclerotic plaque—and not secondary surrogates, which has represented a historical standard of care for nearly 7 decades.
– Andrew Freeman, MD
Director of Cardiovascular Prevention and Wellness at National Jewish Health
Read More
 

Impact on Cardiovascular Care

Being able to measure plaque using CCTA technology is an important step in addressing CAD, but it’s just the beginning. The next step is developing a personalized and optimal treatment plan based on the disease burden. As with cancer and common chronic conditions, this plan varies based on the stage of disease progression – further emphasizing the importance of a staging system for CAD.

 

 

Ready to Learn More?

Schedule a demo with us to explore Cleerly and how you can leverage our technology to improve patient care. 

 
Patents

Cleerly continues to revolutionize heart attack and cardiovascular disease prevention and treatment everyday by inventing world-class technology. Cleerly invests significant time and resources in research and development towards this goal. To protect Cleerly’s research and development efforts, Cleerly has vigorously developed a robust intellectual property portfolio – all part of a strategy for protecting the innovations that make Cleerly an industry leader in cardiovascular disease prevention and treatment.

Cleerly’s products and services may be covered by or for use under one or more of U.S. Patent Nos. 11,922,627, 11,948,301, 12,023,190, 11,861,833, 11,967,078, 11,832,982, 11,690,586, 11,779,292, 11,730,437, 11,672,497, 11,737,718, 11,751,826, 11,660,058, 11,896,415, 11,751,830, 11,751,829, 11,302,001, 11,308,617, 11,238,587, 11,302,002, 11,321,840, 11,341,644, 11,244,451, 11,288,799, 11,276,170, 11,210,786, 11,232,564, 11,367,190, 11,315,247, 11,969,280, 11,094,060, 11,120,550, 11,120,549, 11,132,796, 11,094,061, 11,113,811, 11,501,436, 11,751,831, 11,642,092, 11,759,161, 11,317,883, 11,350,899, 11,766,230, 11,766,229, and 10,813,612, as well as other patents that are pending.

For additional information, please contact legal@cleerlyhealth.com.

Solutions
About

© 2024 Cleerly, Inc.